Pharmacological Profile of a Non-peptidic Dual Inhibitor of Neutral Endopeptidase 24.11 and Endothelin-converting Enzyme
Overview
Authors
Affiliations
CGS 26303 is a potent and structurally unique non-peptidic inhibitor of neutral endopeptidase (NEP) capable of protecting atrial natriuretic peptide (ANP) from enzymatic degradation. In addition, CGS 26303 displays modest endothelin-converting enzyme (ECE) inhibitory activity in vitro. Unlike CGS 24592, a potent but selective NEP inhibitor, CGS 26303 significantly blocks endothelin-1 production in rats after exogenous administration of big ET-1 and reduces the mean arterial pressure in spontaneously hypertensive rats during chronic administration. These results suggest that CGS 26303 represents a new class of therapeutic agents with potential benefits for the treatment of cardiovascular and renal disorders.
Xiong W, Yao W, Gao Z, Liu K Sci Rep. 2022; 12(1):2062.
PMID: 35136075 PMC: 8825803. DOI: 10.1038/s41598-021-04330-4.
Maguire J, Davenport A Br J Pharmacol. 2014; 171(24):5555-72.
PMID: 25131455 PMC: 4290702. DOI: 10.1111/bph.12874.
Wang C, Lee P, Wu B, Wu S, Loh J, Tsai H Biomed Res Int. 2014; 2014:531508.
PMID: 24982890 PMC: 4058103. DOI: 10.1155/2014/531508.
Ferraris D, Sbardella D, Petrera A, Marini S, Amstutz B, Coletta M J Biol Chem. 2011; 286(37):32475-82.
PMID: 21813647 PMC: 3173161. DOI: 10.1074/jbc.M111.271809.
Kirkby N, Hadoke P, Bagnall A, Webb D Br J Pharmacol. 2007; 153(6):1105-19.
PMID: 17965745 PMC: 2275436. DOI: 10.1038/sj.bjp.0707516.